Login
Exscientia plc logo

Exscientia plc

exscientia.ai

No Longer Reporting

The company has not filed an annual or quarterly report since its FY2023 20-F, filed Mar 21, 2024. Its latest SEC filing is a 15-12G from Dec 2, 2024.

The sections below describe the company as of the FY2023 annual report.

What Did They Do?

Designs drug candidates and discovery programs with AI and laboratory experiments for pharmaceutical partners, while advancing its own medicines, mainly in oncology.

How Did They Make Money?

Partners pay upfront when an agreement is signed or a project begins and provide research funding at set intervals. Exscientia may also receive milestone payments and royalties if partnered drug programs reach clinical, regulatory or commercial milestones or make sales.

FY2023 revenue

Who Were Their Customers?

Pharmaceutical partners work directly with Exscientia through drug-discovery and licensing collaborations, including Bristol Myers Squibb, Sanofi and Merck KGaA.

Who Did They Compete With?

Competes with Relay Therapeutics, AbCellera, Schrodinger, Recursion Pharmaceuticals, PathAI, Insitro, Valo Health, Cellarity, XtalPi, BenevolentAI, Absci, and Atomwise

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support